Amin Dipti 4

What Happened Amin Dipti, a director of Lineage Cell Therapeutics (LCTX), received a grant of 125,000 derivative shares on July 1, 2026. The filing shows an acquisition price of $0.00 (no cash paid) and reports $0 as the transaction value. This was an award/grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (appears timely).
• Transaction type: Grant/Award of derivative securities (Code A).
• Amount: 125,000 shares acquired at $0.00; reported value $0.
• Vesting/exercisability: Will vest and become exercisable on the earlier of July 1, 2027 or the issuer’s next annual meeting of shareholders, subject to Dipti’s continuous service (per footnote).
• Shares owned after transaction: Not specified in the filing.
• No indication of sale, tax withholding, or a 10b5‑1 plan in this filing.

Context This is a compensatory award to a director and is not an immediate purchase or sale of common stock. Because the award is a derivative security that vests in the future and is subject to continued service, it does not necessarily reflect immediate ownership or market sentiment. Such grants are common for director compensation.